The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A comparison of first-line combination therapies

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 2, 2005, Pages 275-281

  Weder, Alan B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Antihypertensive therapy; Calcium channel blocker; Clinical trial

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE PLUS BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADULT; AGED; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE; SYSTOLIC HYPERTENSION; TITRIMETRY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 14544278835     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.2.275     Document Type: Review

References (30)

1. WOLFF FW, LINDEMAN RD: Effects of treatment in hypertension. Results of a controlled study. J. Chronic Dis. (1966) 19:230.
2. VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP ON ANTIHYPERTENSIVE AGENTS: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA (1970) 213:1143.
3. AUSTRALIAN NATIONAL BLOOD PRESSURE MANAGEMENT COMMITTEE: The Australian National Therapeutic trial in mild hypertension. Lancet (1980) 1:1267.
4. AMERY A, BURKENHAUGER W, BIXKA P et al.: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet (1985) 1:1349-1354.
5. SHEP COLLABORATIVE RESEARCH GROUP: Prevention of stroke by antihypertensive treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA (1991) 265:3255-3264.
6. STAESSEN JA, FAGARD R, THIJS L et al.: Randomised double-blind comparison of placebo and the active treatment for older patients with isolated systolic hypertension. Lancet (1997) 350 757-764.
7. COLLINS R, PETO R, MACMAHON S et al.: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 335:827-838.
8. BLOOD PRESSURE LOWERING TREATMENT TRIALISTS COLLABORATION: Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet (2000) 355:1955-1964.
9. HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY INVESTIGATORS: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl. J. Med. (2000) 342:145-153.
10. FRANCES GS: ACE inhibition in cardiovascular disease. New Engl. J. Med. (2000) 342:201-202.
11. BRENNER BM, COOPER ME, DEZEEUW D et al., for the RENNAL INVESTIGATORS: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
12. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. (2001) 345:851-860
13. PARVING H-H, LEHNERT M, MORTENSEN JB et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. New Engl. J. Med. (2001) 345:870-878.
14. VIBERTI G, WHEELDON NM: Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation (2002) 106:672-678.
15. THE ALLHAT OFFICERS AND COORDINATORS, for the ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA (2002) 288:2981-2997.
16. DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995-1003.
17. VAN DER HARST P, VOORS AA, VAN VELDHUISEN DJ et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 351:714-717.
18. JAMERSON KA, BAKRIS GL, WUN C-C et al.: Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial. Am. J. Hypertens. (2004) 17:793-801.
19. JULIUS S, KJELDSEN SE, WEBER M et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 363:2022-2031.
20. JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE: the seventh report of the Joint National Committee on Prevention, Detection, evaluation and treatment of high blood pressure. JAMA (2003) 360:2560-2572.
21. EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES COMMITTEE: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1001-1053.
22. VERDECCHIA P, REBOLDI G, ANGELI F et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 43:963-969.
23. EBERLY LE, COHEN JD, PRINEAS R, YANG L: Impact of incident diabetes and incident cardiovascular disease on 18-year mortality: the Multiple Risk Factor Intervention Trial experience. Diabetes Care (2003) 26(3):848-854.
24. WEBER MA, JULIUS S, KJELDSEN SE et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet (2004) 363 2049-2051.
25. DICKERSIN K, RENNIE D: Registering clinical trials. JAMA (2003) 290:516-523.
26. IOANNIDIS JPA, LAU J: The impact of high-risk patients on the results of clinical trials. J. Clin. Epidemiol. (1997) 50 1089-1098.
27. EUROPEAN CAROTID SURGERY TRIALISTS' COLLABORATIVE GROUP: Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final result of the MRC European Carotid Surgery trial (ECST). Lancet (1998) 339:1415-1425.
28. ROTHWELL PM, WARLOW CP, on behalf of THE EUROPEAN CAROTID SURGERY TRIALIST'S COLLABORTIVE GROUP: Prediction of benefit from carotid endarterectomy in individual patients: a risk-modeling study. Lancet (1999) 353:2105-2110.
29. THE GUSTO INVESTIGATORS: An interventional randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. (1993) 329:673-682.
30. KENT DM, HAYWARD RA, GRIFFITH JL et al.: An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am. J. Med. (2002) 113:104-111.